← Back to screener

Pacira BioSciences, Inc. PCRX

Rank #881 · Nasdaq · $1.4B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
57.0
P/E
34.1
P/B
1.85
ROE
5.4%
Op. Margin
13.0%
Debt Ratio
100%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆
Good

P/E 34.1x, P/B 1.85x. Ranks in the top 38% of the universe.

Profitability ★★★☆☆
Average

ROE 5.4%. Ranks in the top 46% of the universe.

Safety ★★★☆☆
Good

Debt ratio 100%. Ranks in the top 39% of the universe.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Valuation is the relative strength (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$0.0B-190.21535
2012$0.0B$-0.0B$-0.0B$-0.0B-155.9-284
2013$0.0B$-0.0B$-0.0B$-0.0B-249.2-95
2014$0.0B$-0.0B$-0.1B$0.0B-126.1266
2015$0.1B$-0.1B$-0.1B$0.1B-62.3235
2016$0.2B$0.0B$-0.0B$0.0B3.8411
2017$0.2B$0.0B$0.0B$0.2B3.8101
2018$0.3B$-0.0B$-0.0B$0.2B-11.6160
2019$0.3B$-0.0B$-0.0B$0.2B-8.7168
2020$0.3B$0.0B$-0.0B$0.3B4.7170
2021$0.4B$0.0B$-0.0B$0.3B2.5204
2022$0.4B$0.0B$0.1B$0.4B10.8379
2023$0.5B$0.1B$0.0B$0.6B16.6146
2024–$0.1B$0.0B$0.7B–96
2025$0.7B$0.1B$0.0B$0.8B13.0100

← See the full screener